Polyacetal-doxorubicin conjugates designed for pH-dependent degradation.

Area of Science:

• Polymer Chemistry
• Drug Delivery Systems
• Biomedical Engineering

Background:

• Polyacetals synthesized from poly(ethylene glycol) (PEG), divinyl ethers, and serinol offer water solubility and hydrolytic lability.
• Amino-pendent polyacetals (APEGs) are pH-degradable and not inherently hepatotropic, suggesting potential for improved anticancer drug delivery.
• Current drug delivery systems, like HPMA copolymer-DOX conjugates, face challenges in tumor targeting and systemic toxicity.

Purpose of the Study:

• To synthesize and characterize a novel polyacetal-doxorubicin (APEG-DOX) conjugate.
• To evaluate the in vitro cytotoxicity of APEG-DOX.
• To compare the in vivo tumor targeting potential of APEG-DOX with an existing HPMA copolymer-DOX conjugate.

Main Methods:

• Synthesis of amino-pendent polyacetals (APEGs) followed by succinoylation.
• Conjugation of doxorubicin (DOX) to APEG-succ using carbodiimide chemistry (EDC).
• In vitro cytotoxicity assays using B16F10 cells and in vivo studies in C57 black mice bearing B16F10 melanoma.

Main Results:

• APEG-DOX conjugates were successfully synthesized with controlled DOX content (3.0-8.5 wt%) and molecular weight (60,000-100,000 g/mol).
• In vitro studies confirmed the biological activity of released DOX, with APEG-DOX showing 10-fold less toxicity than free DOX.
• In vivo, APEG-DOX demonstrated significantly prolonged blood half-life, enhanced tumor accumulation, and reduced liver/spleen uptake compared to HPMA copolymer-DOX.

Conclusions:

• APEG-DOX conjugates represent a promising new class of biodegradable polymer therapeutics.
• These conjugates offer improved tumor targeting and reduced off-target organ accumulation for anticancer agents.
• Further development of APEG-based conjugates is warranted for enhanced cancer therapy.